ReviewOncology research2025
Engendered nanoparticles for treatment of brain tumors.
Review in Oncology research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- BBB-aware stimuli-responsive and biomimetic nanomedicines for glioblastoma.Chinese neurosurgical journal · 2026Review
- Advances in the application of molecular docking in nanomedicine.Journal of computer-aided molecular design · 2026Article
- Current trends in exosomes as therapeutic drug delivery systems.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Targeting the C3 signaling axis of the complement system: immune microenvironment regulation and emerging therapeutic strategies for glioblastoma.Frontiers in immunology · 2026Review
- Omics-enhanced nanomedicine: integrating multi-omics for precision cancer diagnosis and therapy.Discover oncology · 2025Review
- Targeted Nanoparticles for Drug Delivery Across the Blood-Brain Barrier in Early and Late Stages of Alzheimer's Disease: A Review.Molecular neurobiology · 2025Review
- Precision exosome engineering for neurological therapeutics: molecular mechanisms and targeted strategies.Molecular biology reports · 2025Review
- Nanoparticles for Glioblastoma Treatment.Pharmaceutics · 2025Review
- Temperature- and pH-Responsive Poly(NIPAM-Gels (Basel, Switzerland) · 2025Article
- Hybrid Systems of Gels and Nanoparticles for Cancer Therapy: Advances in Multifunctional Therapeutic Platforms.Gels (Basel, Switzerland) · 2025Review
- Safety of Cerebral Intra-Arterial Chemotherapy for the Treatment of Malignant Brain Tumours.Journal of clinical medicine · 2025Article
- Potential mechanisms and clinical applications of static magnetic field therapy in glioma.Frontiers in neurology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Brain metastasis and primary glioblastoma multiforme represent the most common and lethal malignant brain tumors. Its median survival time is typically less than a year after diagnosis. One of the major challenges in treating these cancers is the efficiency of the transport of drugs to the central nervous system. The blood-brain barrier is cooperating with advanced stages of malignancy. The blood-brain barrier poses a significant challenge to delivering systemic medications to brain tumors. Nanodrug delivery systems have emerged as promising tools for effectively crossing this barrier. Additionally, the development of smart nanoparticles brings new hope for cancer diagnosis and treatment. These nanoparticles improve drug delivery efficiency, allowing for the creation of targeted and stimuli-responsive delivery methods. This review highlights recent advancements in nanoparticle and smart nanoparticle technologies for brain cancer treatment, exploring the range of nanoparticles under development, their applications, targeting strategies, and the latest progress in enhancing transport across the blood-brain barrier. It also addresses the ongoing challenges and potential benefits of these innovative approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.